JP2019524671A - 抗ｃｄ１９抗体製剤 - Google Patents

抗ｃｄ１９抗体製剤 Download PDF

Info

Publication number: JP2019524671A
Authority: JP; Japan
Prior art keywords: concentration; formulation; antibody; polysorbate; sequence
Prior art date: 2016-06-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2018567742A

Other languages

English (en)

Japanese (ja)

Inventor

ガリデル，パトリック

ランゲル，アンドレアス

ヘスリング，マルティン

ヴァインフルトナー，ダニエル

ブロックス，ボド

Original Assignee

モルフォシス・アーゲー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-06-27

Filing date

2017-06-27

Publication date

2019-09-05

2017-06-27 Application filed by モルフォシス・アーゲー filed Critical モルフォシス・アーゲー

2019-09-05 Publication of JP2019524671A publication Critical patent/JP2019524671A/ja

2022-05-18 Priority to JP2022081779A priority Critical patent/JP7603201B2/ja

2024-05-23 Priority to JP2024083988A priority patent/JP2024109816A/ja

Status Pending legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 claims abstract description 57
239000000203 mixture Substances 0.000 claims description 192
238000009472 formulation Methods 0.000 claims description 190
229920000136 polysorbate Polymers 0.000 claims description 47
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 46
229930006000 Sucrose Natural products 0.000 claims description 46
229950008882 polysorbate Drugs 0.000 claims description 46
239000005720 sucrose Substances 0.000 claims description 46
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 43
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 43
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 43
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 41
229930195725 Mannitol Natural products 0.000 claims description 41
239000000594 mannitol Substances 0.000 claims description 41
235000010355 mannitol Nutrition 0.000 claims description 41
239000007979 citrate buffer Substances 0.000 claims description 38
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 25
239000000872 buffer Substances 0.000 claims description 22
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
239000008363 phosphate buffer Substances 0.000 claims description 18
238000000034 method Methods 0.000 claims description 16
229920001213 Polysorbate 20 Polymers 0.000 claims description 14
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 14
229940068977 polysorbate 20 Drugs 0.000 claims description 14
201000010099 disease Diseases 0.000 claims description 12
208000035475 disorder Diseases 0.000 claims description 10
206010028980 Neoplasm Diseases 0.000 claims description 7
201000011510 cancer Diseases 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
239000000243 solution Substances 0.000 claims description 4
239000008055 phosphate buffer solution Substances 0.000 claims 2
229940074410 trehalose Drugs 0.000 description 40
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 37
235000018102 proteins Nutrition 0.000 description 23
102000004169 proteins and genes Human genes 0.000 description 23
108090000623 proteins and genes Proteins 0.000 description 23
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 21
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 19
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
238000003860 storage Methods 0.000 description 17
230000000694 effects Effects 0.000 description 15
238000012360 testing method Methods 0.000 description 15
238000003556 assay Methods 0.000 description 13
230000027455 binding Effects 0.000 description 13
238000004108 freeze drying Methods 0.000 description 13
239000012906 subvisible particle Substances 0.000 description 11
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 10
210000003719 b-lymphocyte Anatomy 0.000 description 10
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 9
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 8
108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
150000001413 amino acids Chemical group 0.000 description 8
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 8
239000000427 antigen Substances 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
230000004071 biological effect Effects 0.000 description 8
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 8
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 7
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
238000004255 ion exchange chromatography Methods 0.000 description 7
238000000159 protein binding assay Methods 0.000 description 7
238000013374 right angle light scattering Methods 0.000 description 7
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 6
-1 CVID3 Proteins 0.000 description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
239000012634 fragment Substances 0.000 description 6
238000005259 measurement Methods 0.000 description 6
239000004094 surface-active agent Substances 0.000 description 6
239000007853 buffer solution Substances 0.000 description 5
239000002245 particle Substances 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
235000000346 sugar Nutrition 0.000 description 5
208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 4
230000002776 aggregation Effects 0.000 description 4
238000004220 aggregation Methods 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
230000008859 change Effects 0.000 description 4
230000006240 deamidation Effects 0.000 description 4
206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000012669 liquid formulation Substances 0.000 description 4
238000013507 mapping Methods 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
208000033766 Prolymphocytic Leukemia Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 3
229960002707 bendamustine Drugs 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000007704 transition Effects 0.000 description 3
DIHXSRXTECMMJY-MURFETPASA-N 2-[dimethyl-[(9z,12z)-octadeca-9,12-dienyl]azaniumyl]acetate Chemical group CCCCC\C=C/C\C=C/CCCCCCCC[N+](C)(C)CC([O-])=O DIHXSRXTECMMJY-MURFETPASA-N 0.000 description 2
101710117995 B-lymphocyte antigen CD19 Proteins 0.000 description 2
101100383038 Homo sapiens CD19 gene Proteins 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
230000009471 action Effects 0.000 description 2
238000013378 biophysical characterization Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
229940126534 drug product Drugs 0.000 description 2
239000012636 effector Substances 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000006317 isomerization reaction Methods 0.000 description 2
GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
229960004942 lenalidomide Drugs 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
230000007774 longterm Effects 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
229910001092 metal group alloy Inorganic materials 0.000 description 2
239000000178 monomer Substances 0.000 description 2
238000013483 non-reduced CGE Methods 0.000 description 2
210000004180 plasmocyte Anatomy 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
229960004641 rituximab Drugs 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000001542 size-exclusion chromatography Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
229940121503 tafasitamab Drugs 0.000 description 2
DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 1
LMVGXBRDRZOPHA-UHFFFAOYSA-N 2-[dimethyl-[3-(16-methylheptadecanoylamino)propyl]azaniumyl]acetate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O LMVGXBRDRZOPHA-UHFFFAOYSA-N 0.000 description 1
TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 description 1
SNQVCAOGQHOSEN-UHFFFAOYSA-N 2-[methyl(octadecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(O)=O SNQVCAOGQHOSEN-UHFFFAOYSA-N 0.000 description 1
DIROHOMJLWMERM-UHFFFAOYSA-N 3-[dimethyl(octadecyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O DIROHOMJLWMERM-UHFFFAOYSA-N 0.000 description 1
208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
201000004085 CLL/SLL Diseases 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
235000017858 Laurus nobilis Nutrition 0.000 description 1
201000003791 MALT lymphoma Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
235000005212 Terminalia tomentosa Nutrition 0.000 description 1
244000125380 Terminalia tomentosa Species 0.000 description 1
238000011111 UV-scan method Methods 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
210000005006 adaptive immune system Anatomy 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000013103 analytical ultracentrifugation Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000001818 capillary gel electrophoresis Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000011712 cell development Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 1
238000000978 circular dichroism spectroscopy Methods 0.000 description 1
230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000004590 computer program Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000013078 crystal Substances 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000009509 drug development Methods 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
201000003444 follicular lymphoma Diseases 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
229910000856 hastalloy Inorganic materials 0.000 description 1
230000036541 health Effects 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
210000003297 immature b lymphocyte Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
125000005645 linoleyl group Chemical group 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
208000021937 marginal zone lymphoma Diseases 0.000 description 1
210000003519 mature b lymphocyte Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
NZXVYLJKFYSEPO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-16-methylheptadecanamide Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)NCCCN(C)C NZXVYLJKFYSEPO-UHFFFAOYSA-N 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
238000001225 nuclear magnetic resonance method Methods 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
238000013379 physicochemical characterization Methods 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229940044519 poloxamer 188 Drugs 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
210000001948 pro-b lymphocyte Anatomy 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000004845 protein aggregation Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000012430 stability testing Methods 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
238000003696 structure analysis method Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000009269 systemic vascular permeability Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940104261 taurate Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
229940074409 trehalose dihydrate Drugs 0.000 description 1
239000012905 visible particle Substances 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Mycology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

JP2018567742A 2016-06-27 2017-06-27 抗ｃｄ１９抗体製剤 Pending JP2019524671A (ja)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
JP2022081779A JP7603201B2 (ja)	2016-06-27	2022-05-18	抗ｃｄ１９抗体製剤
JP2024083988A JP2024109816A (ja)	2016-06-27	2024-05-23	抗ｃｄ１９抗体製剤

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP16176322		2016-06-27
EP16176322.2		2016-06-27
PCT/EP2017/065819 WO2018002031A1 (en)	2016-06-27	2017-06-27	Anti-cd19 antibody formulations

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2022081779A Division JP7603201B2 (ja)	2016-06-27	2022-05-18	抗ｃｄ１９抗体製剤

Publications (1)

Publication Number	Publication Date
JP2019524671A true JP2019524671A (ja)	2019-09-05

Family

ID=56368805

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2018567742A Pending JP2019524671A (ja)	2016-06-27	2017-06-27	抗ｃｄ１９抗体製剤
JP2022081779A Active JP7603201B2 (ja)	2016-06-27	2022-05-18	抗ｃｄ１９抗体製剤
JP2024083988A Pending JP2024109816A (ja)	2016-06-27	2024-05-23	抗ｃｄ１９抗体製剤

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
JP2022081779A Active JP7603201B2 (ja)	2016-06-27	2022-05-18	抗ｃｄ１９抗体製剤
JP2024083988A Pending JP2024109816A (ja)	2016-06-27	2024-05-23	抗ｃｄ１９抗体製剤

Country Status (26)

Country	Link
US (2)	US11352423B2 (sl)
EP (2)	EP3909985A1 (sl)
JP (3)	JP2019524671A (sl)
KR (2)	KR102533875B1 (sl)
CN (2)	CN115998859A (sl)
AU (2)	AU2017289085B2 (sl)
CA (1)	CA3029137A1 (sl)
CY (1)	CY1124521T1 (sl)
DK (1)	DK3475303T3 (sl)
ES (1)	ES2874640T3 (sl)
HR (1)	HRP20210945T1 (sl)
HU (1)	HUE054296T2 (sl)
IL (1)	IL263764B2 (sl)
LT (1)	LT3475303T (sl)
MA (1)	MA45450B1 (sl)
MD (1)	MD3475303T2 (sl)
MX (1)	MX2018016362A (sl)
PL (1)	PL3475303T3 (sl)
PT (1)	PT3475303T (sl)
RS (1)	RS62035B1 (sl)
RU (1)	RU2748024C2 (sl)
SG (2)	SG10201912369QA (sl)
SI (1)	SI3475303T1 (sl)
SM (1)	SMT202100317T1 (sl)
WO (1)	WO2018002031A1 (sl)
ZA (1)	ZA201900483B (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6862422B2 (ja)	2015-08-21	2021-04-21	モルフォシス・アーゲー	組み合わせおよびその使用
AU2020225202B2 (en)	2019-02-18	2023-10-26	Eli Lilly And Company	Therapeutic antibody formulation
EP4038194A1 (en)	2019-10-04	2022-08-10	Ultragenyx Pharmaceutical Inc.	Methods for improved therapeutic use of recombinant aav
JP2022554324A (ja)	2019-10-31	2022-12-28	モルフォシス・アーゲー	抗ｃｄ１９抗体及びガンマデルタｔ細胞を含む抗腫瘍併用療法
CA3181827A1 (en)	2020-06-22	2021-12-30	Morphosys Ag	Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint
CA3187272A1 (en)	2020-10-08	2022-04-14	Thorsten Ross	Trispecific binders
JP2024529381A (ja)	2021-07-30	2024-08-06	アフィメドゲーエムベーハー	デュプレックスボディ
WO2023073645A1 (en)	2021-10-29	2023-05-04	Takeda Pharmaceutical Company Limited	Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
AU2022382368A1 (en)	2021-11-03	2024-05-02	Affimed Gmbh	Bispecific cd16a binders
WO2023215674A1 (en) *	2022-05-03	2023-11-09	Xencor, Inc.	Methods for treating lymphoma
WO2024038115A1 (en)	2022-08-17	2024-02-22	Morphosys Ag	Therapy comprising anti-cd19 antibody and ezh2 modulators
WO2024180511A1 (en) *	2023-03-02	2024-09-06	Novetide Ltd.	Process for preparation of glp-1 peptides having controlled particle size

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2010500882A (ja) *	2006-08-14	2010-01-14	ゼンコー・インコーポレイテッド	Ｃｄ１９を標的とする最適化抗体
WO2015157286A1 (en) *	2014-04-07	2015-10-15	Seattle Genetics, Inc.	Stable formulations for anti-cd19 antibodies and antibody-drug conjugates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0138854B1 (en)	1983-03-08	1992-11-04	Chiron Mimotopes Pty. Ltd.	Antigenically active amino acid sequences
EP1461423B1 (en)	2001-12-03	2008-05-14	Amgen Fremont Inc.	Antibody categorization based on binding characteristics
US20080260731A1 (en) *	2002-03-01	2008-10-23	Bernett Matthew J	Optimized antibodies that target cd19
US7902338B2 (en)	2003-07-31	2011-03-08	Immunomedics, Inc.	Anti-CD19 antibodies
US7109304B2 (en)	2003-07-31	2006-09-19	Immunomedics, Inc.	Humanized anti-CD19 antibodies
WO2007002223A2 (en)	2005-06-20	2007-01-04	Medarex, Inc.	Cd19 antibodies and their uses
DK1966245T3 (da)	2005-12-30	2011-07-18	Merck Patent Gmbh	Anti-CD19-Antistoffer med reduceret immunogenicitet
PL2066349T3 (pl)	2006-09-08	2012-09-28	Medimmune Llc	Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
AU2008260498B2 (en)	2007-05-30	2012-11-29	Xencor, Inc.	Methods and compositions for inhibiting CD32b expressing cells
US9096651B2 (en)	2007-09-26	2015-08-04	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substitution in CDR
SI2211904T1 (sl)	2007-10-19	2016-12-30	Seattle Genetics, Inc.	CD19 vezavna sredstva in njihove uporabe
CN102421800A (zh)	2009-02-23	2012-04-18	格兰马克药品股份有限公司	结合cd19的人源化抗体及其用途
US20120148576A1 (en) *	2009-03-06	2012-06-14	Medlmmune, Llc	Humanized anti-cd 19 antibody formulations
WO2011147834A1 (en)	2010-05-26	2011-12-01	Roche Glycart Ag	Antibodies against cd19 and uses thereof
EP2409993A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2524929A1 (en)	2011-05-17	2012-11-21	Sanofi	Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
JP6511609B2 (ja)	2013-03-13	2019-05-22	ジェネンテック，インコーポレイテッド	抗体製剤
CA3113172A1 (en)	2013-03-13	2014-10-02	Genentech, Inc.	Screen for compound that prevents protein oxidation based on comparison with l-tryptophan
US10513555B2 (en) *	2013-07-04	2019-12-24	Prothena Biosciences Limited	Antibody formulations and methods
ES2768614T3 (es)	2013-09-27	2020-06-23	Hoffmann La Roche	Formulaciones de anticuerpos anti-PDL1
WO2015075201A1 (en) *	2013-11-21	2015-05-28	Genmab A/S	Antibody-drug conjugate lyophilised formulation

2017
- 2017-06-27 SG SG10201912369QA patent/SG10201912369QA/en unknown
- 2017-06-27 DK DK17735440.4T patent/DK3475303T3/da active
- 2017-06-27 SM SM20210317T patent/SMT202100317T1/it unknown
- 2017-06-27 RS RS20210748A patent/RS62035B1/sr unknown
- 2017-06-27 JP JP2018567742A patent/JP2019524671A/ja active Pending
- 2017-06-27 US US16/310,555 patent/US11352423B2/en active Active
- 2017-06-27 KR KR1020197002043A patent/KR102533875B1/ko active Active
- 2017-06-27 PT PT177354404T patent/PT3475303T/pt unknown
- 2017-06-27 LT LTEP17735440.4T patent/LT3475303T/lt unknown
- 2017-06-27 EP EP21167818.0A patent/EP3909985A1/en active Pending
- 2017-06-27 CA CA3029137A patent/CA3029137A1/en active Pending
- 2017-06-27 RU RU2019100221A patent/RU2748024C2/ru active
- 2017-06-27 PL PL17735440T patent/PL3475303T3/pl unknown
- 2017-06-27 CN CN202211458395.0A patent/CN115998859A/zh active Pending
- 2017-06-27 SG SG11201810429UA patent/SG11201810429UA/en unknown
- 2017-06-27 IL IL263764A patent/IL263764B2/en unknown
- 2017-06-27 MD MDE20190533T patent/MD3475303T2/ro unknown
- 2017-06-27 MA MA45450A patent/MA45450B1/fr unknown
- 2017-06-27 ES ES17735440T patent/ES2874640T3/es active Active
- 2017-06-27 EP EP17735440.4A patent/EP3475303B1/en active Active
- 2017-06-27 WO PCT/EP2017/065819 patent/WO2018002031A1/en unknown
- 2017-06-27 SI SI201730801T patent/SI3475303T1/sl unknown
- 2017-06-27 KR KR1020237016157A patent/KR20230074823A/ko not_active Ceased
- 2017-06-27 HU HUE17735440A patent/HUE054296T2/hu unknown
- 2017-06-27 MX MX2018016362A patent/MX2018016362A/es unknown
- 2017-06-27 AU AU2017289085A patent/AU2017289085B2/en active Active
- 2017-06-27 CN CN201780039737.6A patent/CN109415440B/zh active Active
2019
- 2019-01-23 ZA ZA2019/00483A patent/ZA201900483B/en unknown
2021
- 2021-06-14 HR HRP20210945TT patent/HRP20210945T1/hr unknown
- 2021-06-14 CY CY20211100532T patent/CY1124521T1/el unknown
2022
- 2022-03-22 US US17/700,809 patent/US20220213190A1/en active Pending
- 2022-05-18 JP JP2022081779A patent/JP7603201B2/ja active Active
2024
- 2024-05-23 JP JP2024083988A patent/JP2024109816A/ja active Pending
- 2024-07-24 AU AU2024205042A patent/AU2024205042A1/en active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2010500882A (ja) *	2006-08-14	2010-01-14	ゼンコー・インコーポレイテッド	Ｃｄ１９を標的とする最適化抗体
WO2015157286A1 (en) *	2014-04-07	2015-10-15	Seattle Genetics, Inc.	Stable formulations for anti-cd19 antibodies and antibody-drug conjugates

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLELAND J L: "A SPECIFIC MOLAR RATIO OF STABILIZER TO PROTEIN IS REQUIRED FOR STORAGE STABILITY OF A 以下備考", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. VOL:90, NR:3, JPN5019006016, March 2001 (2001-03-01), US, pages 310 - 321, ISSN: 0004684287 *
CONNOLLY BRIAN D: "PROTEIN AGGREGATION IN FROZEN TREHALOSE FORMULATIONS: EFFECTS OF COMPOSITION, COOLING RATE, 以下備考", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. VOL:104, NR:12, JPN5019006017, December 2015 (2015-12-01), US, pages 4170 - 4184, ISSN: 0004684286 *
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 185, JPN6021020280, 1999, pages 129 - 188, ISSN: 0004684289 *
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 91(4), JPN6021020276, 2002, pages 914 - 922, ISSN: 0004684285 *
ZHOU CHEN: "REDUCED SUBVISIBLE PARTICLE FORMATION IN LYOPHILIZED INTRAVENOUS IMMUNOGLOBULIN 以下備考", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. VOL:105, NR:8, JPN5019006015, 9 June 2016 (2016-06-09), pages 2302 - 2309, ISSN: 0004684288 *

Also Published As

Publication number	Publication date
JP2024109816A (ja)	2024-08-14
US20220213190A1 (en)	2022-07-07
SG11201810429UA (en)	2018-12-28
HRP20210945T1 (hr)	2021-09-17
CA3029137A1 (en)	2018-01-04
EP3475303A1 (en)	2019-05-01
IL263764B1 (en)	2024-05-01
ES2874640T3 (es)	2021-11-05
CY1124521T1 (el)	2022-07-22
MA45450B1 (fr)	2021-04-30
KR20230074823A (ko)	2023-05-31
DK3475303T3 (da)	2021-05-31
JP7603201B2 (ja)	2024-12-20
JP2022119854A (ja)	2022-08-17
IL263764B2 (en)	2024-09-01
KR20190021373A (ko)	2019-03-05
EP3475303B1 (en)	2021-04-14
RU2019100221A (ru)	2020-07-28
HUE054296T2 (hu)	2021-08-30
EP3909985A1 (en)	2021-11-17
CN109415440A (zh)	2019-03-01
US11352423B2 (en)	2022-06-07
AU2017289085A1 (en)	2018-12-13
AU2017289085B2 (en)	2024-07-18
IL263764A (en)	2019-01-31
LT3475303T (lt)	2021-06-25
MX2018016362A (es)	2019-04-22
RS62035B1 (sr)	2021-07-30
RU2019100221A3 (sl)	2020-11-30
WO2018002031A1 (en)	2018-01-04
SMT202100317T1 (it)	2021-07-12
CN115998859A (zh)	2023-04-25
CN109415440B (zh)	2022-12-06
MD3475303T2 (ro)	2021-09-30
SI3475303T1 (sl)	2021-12-31
PL3475303T3 (pl)	2021-12-06
ZA201900483B (en)	2021-06-30
US20190322742A1 (en)	2019-10-24
RU2748024C2 (ru)	2021-05-19
SG10201912369QA (en)	2020-02-27
AU2024205042A1 (en)	2024-08-15
KR102533875B1 (ko)	2023-05-18
PT3475303T (pt)	2021-06-25

Publication	Publication Date	Title
JP7603201B2 (ja)	2024-12-20	抗ｃｄ１９抗体製剤
IL275038B2 (en)	2023-03-01	Formulation for anti-antibody alpha 4 in cell 7
CN110732023A (zh)	2020-01-31	一种her2抗体药物组合物及其用途
US11498961B2 (en)	2022-11-15	SOST antibody pharmaceutical composition and uses thereof
WO2018223958A1 (zh)	2018-12-13	一种含c-Met抗体药物偶联物的药物组合物及其用途
CA3105360A1 (en)	2020-01-09	Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer
CN112839961B (zh)	2023-04-04	一种cd40抗体药物组合物及其用途
US20230090868A1 (en)	2023-03-23	Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
NZ789731A (en)	2022-07-01	Anti-CD19 antibody formulations
NZ748681A (en)		Anti-cd19 antibody formulations
WO2024083074A1 (en)	2024-04-25	Formulations containing anti-tigit antibody and methods of use thereof
WO2025061145A1 (zh)	2025-03-27	抗her3抗体药物偶联物治疗肿瘤的用途和方法
CA3237175A1 (en)	2023-05-11	Corticosteriod reduction in treatment with anti-cd38 antibodies

Legal Events

Date	Code	Title	Description
2020-06-26	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200626
2021-06-01	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210601
2021-09-01	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210901
2021-10-28	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211028
2021-12-01	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211201
2022-01-18	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220118